Pembrolizumab for the treatment of gastric cancer
Pembrolizumab for the treatment of gastric cancer
复制标题
DOI：
10.1080/14737140.2018.1526084
复制
发表时间：
2018-12-02
影响因子：
3.3
通讯作者：
Benson, Al B., III
中科院分区：
文献类型：
--
作者：
Kamath, Suneel D.;Kalyan, Aparna;Benson, Al B., III
胃癌是免疫治疗已显示有意义的胃肠道恶性肿瘤之一。Pembrolizumab是第一个也是唯一一个被fda批准用于胃癌的免疫检查点抑制剂。涵盖领域：本综述总结了免疫检查点抑制剂治疗晚期和转移性胃癌的现有和新出现的临床证据，重点是派姆单抗。专家评论：Pembrolizumab在局部晚期和转移性胃癌的三线治疗中显示出令人印象深刻的活性。目前正在研究将其作为前期治疗与化疗联合使用。本文讨论了分子改变和肿瘤免疫微环境作为胃癌免疫治疗反应预测因子的新认识。综述了胃黏膜生态失调对胃癌发生的影响以及肠道微生物群对免疫治疗反应的调节。
Introduction: Gastric cancer is one of a few gastrointestinal malignancies in which immunotherapy has shown meaningful activity. Pembrolizumab is the first and only immune checkpoint inhibitor to be FDA-approved in gastric cancer. Areas Covered: This review summarizes the current and emerging clinical evidence for immune checkpoint inhibitors in advanced and metastatic gastric cancer, with a focus on pembrolizumab. Expert Commentary: Pembrolizumab has shown impressive activity in the third-line treatment of locally advanced and metastatic gastric cancer. It is currently being studied as upfront therapy in combination with chemotherapy. The emerging understanding of the molecular alterations and tumor immune microenvironment as predictors of immunotherapy response in gastric cancer are discussed. The impact of gastric mucosal dysbiosis on gastric carcinogenesis and the modulation of immunotherapy response by the gut microbiome are also reviewed.